10 most expensive drugs for Medicare Part B

Medicare Part B covers drugs that are administered by healthcare providers, such as infused or injected cancer drugs. 

The 10 drugs that cost Medicare Part B the most in 2018, according to a Moody's Investors Service report: 

1. Eylea (Regeneron) — $2.57 billion 
2. Keytruda (Merck) — $1.81 billion 
3. Opdivo (Bristol-Myers Squibb) — $1.72 billion
4. Rituxan (Roche) — $1.70 billion 
5. Prolia (Amgen) — $1.42 billion 
6. Neulasta (Amgen) — $1.37 billion 
7. Lucentis (Roche) — $1.22 billion 
8. Remicade (Johnson & Johnson) — $1.15 billion 
9. Avastin (Roche) — $1.01 billion 
10. Herceptin (Roche) — $822 million